Actively Recruiting
Phase Ia Study Evaluating Safety, Tolerability, and Pharmacokinetics of HW241045 Tablets as a Single Dose in Healthy Adults
Led by Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Updated on 2026-03-04
56
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying HW241045 in a Phase Ia clinical trial to evaluate its safety, tolerability, and how it is processed in the body after a single dose. This randomized, double-blind, placebo-controlled study involves healthy adult volunteers aged 18 to 55 years to better understand the effects of this drug compared to a placebo. Participants will receive a single oral dose of either HW241045 or a placebo. The study is designed with two groups one receiving the experimental drug and the other receiving placebo, both under blinded conditions to ensure unbiased results. The trial is conducted at a single center and uses a quadruple masking approach. During the study, participants will be closely monitored for any treatment-emergent adverse events within 48 hours after dosing. Assessments include safety checks, tolerability evaluations, and pharmacokinetic measurements. Participants health will be carefully observed during this period to understand the drugs effects and side effects. The total duration of participation is determined by these assessments and monitoring schedules.
CONDITIONS
Brief Title
A Phase Ia Clinical Trial of HW241045
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here